MCRB vs. RZLT, ERAS, TECX, SLDB, ITOS, ETON, ALT, CMPX, CYRX, and RVNC
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Rezolute (RZLT), Erasca (ERAS), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Altimmune (ALT), Compass Therapeutics (CMPX), CryoPort (CYRX), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry.
Seres Therapeutics vs. Its Competitors
Seres Therapeutics (NASDAQ:MCRB) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.
Seres Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Rezolute's return on equity of -70.09% beat Seres Therapeutics' return on equity.
In the previous week, Rezolute had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Rezolute and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.11 beat Rezolute's score of 0.34 indicating that Seres Therapeutics is being referred to more favorably in the media.
Seres Therapeutics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics currently has a consensus price target of $73.67, suggesting a potential upside of 496.49%. Rezolute has a consensus price target of $11.83, suggesting a potential upside of 125.40%. Given Seres Therapeutics' higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than Rezolute.
59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by company insiders. Comparatively, 18.4% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Rezolute beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MCRB) was last updated on 7/10/2025 by MarketBeat.com Staff
Free MCRB Stock Alerts